YahooAugust 13, 2026 at 3:27 PM NY2 Months Ago
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
